Melatonin Shields Mitochondria From Radiation Damage
Melatonin as a radioprotectant against mitochondrial damage 🤔"Melatonin can protect against irradiation-induced mitochondrial damage, suggesting utility for mitigating the health effects of accidental radiation exposure." https://t.co/XHZYDE916a
Malaria Vaccine Team Faced Funding Delays at Every Stage
“The researchers who worked on this malaria vaccine struggled at every step of the process to get faster funding.” ~@salonium
ByteDance's AI-Designed Therapies Spotlight Global Progress
ByteDance’s drug unit presents AI-designed therapies at global conferences Yes this is reality of AI applications, but we are "winning" by slowng Chinese company progress on AI? https://t.co/G3lIeOAddU
KRAS G12D Drug Shrinks Tumors, Delays Progression
Setidegrasib, an investigational therapy targeting KRAS G12D, demonstrated tumor shrinkage and delayed disease progression in early trials for advanced lung and pancreatic cancers, offering a potential new approach for hard-to-treat mutations. oncology
R‑MDDMA Boosts Neuroplasticity and Ant
methylated MDMA analog in animals R-MDDMA "still promoted structural neuroplasticity in cortical neurons, facilitated fear extinction learning, and produced sustained antidepressant-like effects" did not directly activate 5-HT2B receptors https://t.co/w0ltV7VXQL
AGEs Trigger SIRT1 Loss, Accelerating Osteoarthritis via RANKL
SIRT1 Downregulation by Advanced Glycation End Products Activates RANKL-Dependent Osteoclast Signaling and Drives Chondrocyte Senescence During Osteoarthritis Development "Targeting this mechanism may offer new therapeutic opportunities for delaying age-related OA progression." https://t.co/HB2nmyZ43u
AI Enables Building New Species Like Software
Adrian Woolfson said at the World Government Summit that his team used AI to create an entirely new species from scratch. Here are 8 things he said about what comes next for synthetic biology: 1) Building species the same way we build...
Modern Meds Are Precise; Older Drugs Are Broad-Spectrum
Modern drugs tend to be very tightly targeted. Older drugs like metformin or Tylenol cut a wider swath.
Allosteric Switch in TB Enzyme Opens New Drug Target
A newly identified allosteric switch in the ICL2 enzyme of Mycobacterium tuberculosis reveals a potential pathway for targeting drug-resistant TB, offering insight into protein regulation unique to the bacterium. structuralbiology
CNS Gene Therapies Showcase Tau-Targeted VY170
CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease https://t.co/oQ5MCd5piS https://t.co/8KeWSTJ1q7
TMDX’s OCS Tech Drives Rapid Adoption, Pressures Valuation
$TMDX reports Tuesday after the close This is the only company on earth that keeps a donor heart, lung, or liver beating outside the body Not a metaphor... the organ stays warm and oxygenated e2e The number to watch on Tuesday isn't rev,...
FDA Approves Early, yet ARVN, PFE Lack Partner
FDA approves vepdegrestrant one month early. $ARVN and $PFE still haven't found (or disclosed) a third-party company to commercialize it. What a world...
ARCH Backs Mental‑health IPO, Celebrating Early Investment Success
Congrats to Daphne Zohar and team, and Steve Paul for an amazing IPO to fuel new drugs for mental health and brain disorders. ARCH invested early here because of the team, platform, and clinical need.
T‑cell Vesicles Deliver DNA, Converting Cold Tumors Hot
In cancer, activated T cells release abundant extracellular vesicles that transfer DNA to the nucleus of tumor and immune (dendritic) cells, turning tumors from cold to hot. An immunotherapy in the works. @Cancer_Cell https://t.co/mHcahijOJC https://t.co/oPT6d7lrFM https://t.co/I0egYxZold
Early Trial RNA‑seq Data: Exciting Yet Requires Caution
🧵 You just got your hands on early clinical trial RNA-seq data. Excited? You should also be cautious. Here's why. 👇 https://t.co/GjA8XIYcVQ
Biotech IPOs Surge, Exposing Wall St Underestimation
Three biotech IPOs this week. Each one raised its number of shares and priced atop range. Suggests that Wall St is slightly underestimating investor interest in new biotech issues.
AI Chatbots Capture Poorer Symptom Detail than Doctors
Symptoms reported to an AI chatbot were of lesser quality than reported to a physician, results of a randomized trial of 500 participants across multiple models https://t.co/WXP4R3y9HA https://t.co/l2hLT76AJB
High‑dose Semaglutide Cuts Alcohol Use in RCT
Clinicians and patients saw big reductions in alcohol intake when starting GLP-1 medicine. This is the first randomized trial to look at the high dose of semaglutide. There was a study a couple years back looking at a lower dose....
Enzymatic DNA Synthesis Frees Synthetic Biology Design
“You should design for the biology you want to build, not for the process limitations of a supplier that’s been holding the field back.” That line from @Jason_Gammack , CEO of @AnsaBio , gets right to the heart of one...
FDA Approves First Non‑antipsychotic for Dementia Agitation
⚕️ FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia 🔗https://t.co/cPNtkiSXBs 🌐 #DHPSP #Pharma #Healthcare https://t.co/KsBKc45ekk
Interim Data Hint Weaker PFS; Selloff Caps Losses
Leerink's Daina Graybosch on $SMMT "... In our base case scenario of the company’s likely statistical design choices and enrollment timing, not hitting statistical significance at this interim suggests a degradation in PFS Hazard Ratio (HR) of ~10 percentage points...
90s Club Drug K Now Legit Antidepressant, PSIL up 20%
As someone who has had some fun, semi-memorable nights at NYC clubs Tunnel and Limelight in the '90s, it's hard to believe "K" has turned into a legit medication (and has $PSIL up 20% in April). That said, anyone who...
Decoding Ovarian Aging to Extend Reproductive Lifespan
Ovarian aging: Mechanisms and strategies to extend reproductive lifespan Core mechanisms include genomic instability, epigenetic noise, mitochondria, inflammation, senescence & fibrosis PhD student Maria Lopez @sinclarfriends is working on it https://t.co/tuJbQb2Xcu https://t.co/K1GlXY4KsY
Blood Test Pinpoints Amyloid‑to‑tau Transition in Alzheimer’s
Tracking the turning point in Alzheimer’s disease A blood biomarker reveals the mechanistic shift from amyloid to tau pathology https://t.co/p2UfYwgBHW https://t.co/Kuu82UPrFv
Semaglutide Cuts Heavy Drinking and Cravings in AUD
GLP-1 Drug Semaglutide (Ozempic, Wegovy) Reduced Heavy Drinking & Craving in Adults with Alcohol Use Disorder https://t.co/FYRkjWYhJQ https://t.co/cGtEajk9lp
Calorie Restriction Deactivates Complement C3a, Slowing Inflammaging
"complement C3a reduction is a metabolically regulated inflammatory checkpoint that can be harnessed to attenuate inflammaging" Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging https://t.co/FxGHE6Obm0
Ozempic Cuts Drinking in Obese AUD Patients
First randomized trial to show Ozempic reduces alcohol consumption in people seeking treatment for alcohol use disorder. Placebo-controlled, double-blind. Participants with BMI >30 kg/m2. https://t.co/M9Pk2gzKHD @TheLancet https://t.co/OT660QIn6N
GLP‑1 Drugs Cause Less Muscle Loss than Assumed
Do GLP-1 drugs really cause muscle loss? Turns out perhaps less than what we thought… here’s what you need to know, from: https://t.co/VwrRxnoblW https://t.co/M2RaE1f3EG
AI Designs Life Using only 19 Amino Acids
Not something you'd see everyday—changing the alphabet of life. All of life organisms are are built from 20 amino acids. Now genAI is enabling life to be built with 19 amino acids, making isoleucine dispensable. @ScienceMagazine https://t.co/7CBn0Xhuxs https://t.co/tkxtCrFx9Y
Interim PFS Review Confirms Study Continuation
$SMMT ivo HARMONi-3 update on squamous subgroup interim PFS analysis: "At this early interim PFS analysis reviewed exclusively by the Independent Data Monitoring Committee (iDMC), the iDMC recommended that the study continue as planned."
AXSM Jumps 10.5% on Approval and Analyst Boost
$AXSM up over 10.5% on approval, calls hit nicely from recent write-up on this catalyst play https://t.co/H2E75g3iRB
P‑tau217 Blood Test Predicts Alzheimer’s Risk Early
Good summary of p-tau217, the breakthrough blood test to predict risk of Alzheimer's in people well before onset of symptoms @ScienceMagazine https://t.co/qVJtYR4bnz https://t.co/OhjLExTroG
Pharma Power Shifts: Controlling Diseases, Not Just Assets
Most pharma pipeline analysis is spreadsheet theater. I used AI to look at the 2020 → 2026 shift. The real question is not: Who has the most assets? It is: Who controls the disease category? GLP-1s are a metabolic land grab. Oncology is becoming a platform stack. Trials...
UniQure Pursues UK Approval for Huntington’s Gene Therapy
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy https://t.co/plxdEw43FD by @Lilah_Alvarado $QURE + 22% #GeneTherapy
Pinetree Therapeutics: Promising Biotech Worth Watching
A biotech you need to keep an eye on... Pinetree Therapeutics $AZN https://t.co/wVt9XMcr0Z (disclosure: SAB member)
Wine‑and‑Cheese Fundraising: A Fresh Biotech Investor Model
This was a cool event. Took a different tact, brought new and very seasoned investors together over wine and cheese, and raised funds @AnywhereDx …Maybe an interesting future model for raising funds in a biotech atmosphere that feels increasingly disconnected.
Top 15 Biopharma R&D Players and Late‑Stage Prospects
My annual report on the top 15 R&D players in biopharma is out. It's a beast at some 9000 words, but if you're interested in the top prospects in the late-stage pipeline, I got a bunch for you. The stakes...
Irisin Hormone Reverses Obesity and Insulin Resistance
Irisin, a hormone released by muscle during exercise, reverses obesity and insulin resistance in mice -- without cutting food intake or causing muscle loss. As a medical school professor, I find this striking. We have spent a decade asking how to...
Gene Therapy Soon as Routine as Everyday Surgery
Eric Kelsic envisions the future of gene therapy will be viewed in the “the same way that many of us have had some form of surgery at certain points in our life.” As therapies become safer and more effective, the decision...
Trump's Psychedelic Order Preserves FDA Oversight Balance
My op ed in today's @WashPost - "Trump’s executive order on psychedelics strikes a healthy balance: The president preserved the FDA's role, even as some want the agency's gatekeeping dismantled." https://t.co/9hH7kz107J
Serena-6 Shows Unexpected Immature OS Curves
$AZN Serena-6 immature OS curves as revealed at the adcom. Not sure we've seen these before. https://t.co/L9oAQxhrh9
DNA Nano‑Ring Precisely Captures and Orients Membrane Proteins
A new DNA nano-ring platform enables precise capture and orientation of individual membrane proteins, advancing the study of these vital cellular gatekeepers and opening new possibilities in medicine, imaging, and synthetic biology. nanotechnology
Plasmid Editor Adds API for AI-Driven Real-Time Editing
A feature I'm working on adding to my plasmid editor is an API for agent work. This lets your favorite Ai do work on the files in your plasmid editor directly, and the results update in your open GUI in...
New GLP‑5 Study Is Only Mouse
A friendly reminder, just because that new Nature study on a quintuple agonist (LOL GET READY FOR "GLP-5" discourse) is out today: It's a study on MICE. MICE TESTING IS NOT HUMAN TESTING. IT'S JUST MICE.
Year Two Funding Crisis: Grants Dry, Competition Rises
With federal research funding cuts, the first year of Trump 2.0 was tough. Year 2 is in some ways grimmer, a @statnews survey shows. Bridge funding is drying up, existing grants are ending & competition for fewer new grants is...
Better Prediction of Type 1 Diabetes Boosts Prevention Prospects
A jump in our ability to predict Type 1 autoimmune diabetes should help future preventive strategies @NatureGenet https://t.co/ako2Ic46QW https://t.co/XbW26qu5LE
Akeso’s ASCO Plenary Raises Questions on Lung Cancer Data
This week's Biotech Scorecard: An #ASCO26 mystery: What does Akeso’s primo plenary spot say about its ivonescimab lung cancer survival data? $SMMT If the news was good, we'd have heard by now, right? Or, is Akeso just being ultra conservative?...
High Accuracy in Omics May Be Illusory
The pitfalls of class prediction in omics 🧵 1/ You think you’ve built the perfect omics predictor. The accuracy is high. The p-value is low. But is it real—or just a story your data whispered back? https://t.co/LGNWQMKOfv
Remember Craig: Push Bold Biotech Innovation
RIP to one of our few ballers in biotech. I hope we use Craig's memory to not be afraid to go big in biotech. The world needs our tech and it's a loss to not have his voice...
Sevabertinib Shows
EGFR’s Poor Sibling {Editorial} [April 15, 2026] @DCarboneMD @NEJM https://t.co/DjV4gAtKMk #lcsm #PrecisionMedicine RE: #NCT05099172 Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer https://t.co/63kCdZ6JOJ